BridgeBio Pharma, Inc. (BBIO) Guidance & Earnings Results
On 2026-02-24 BridgeBio Pharma, Inc. raised guidance: "Multiple NDA submissions and launches anticipated in…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BBIOBridgeBio Pharma, Inc.Follow BBIO — free
—
Price chart with a free account
- Market cap
- 13.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 24 Feb 26 | Raised | Multiple NDA submissions and launches anticipated in 2026/2027 · full year |
BridgeBio Pharma, Inc. — questions
- What guidance did BridgeBio Pharma, Inc. give?
- On 2026-02-24: "Multiple NDA submissions and launches anticipated in 2026/2027"
- When does BridgeBio Pharma, Inc. report earnings?
- BridgeBio Pharma, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from BridgeBio Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.